A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson's Disease.

Trial Profile

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson's Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Levodopa/carbidopa (Primary) ; Levodopa/carbidopa/entacapone
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ASCEND-PD
  • Sponsors IMPAX Laboratories
  • Most Recent Events

    • 21 Apr 2016 Results (pooled analysis of ADVANCE-PD and ASCEND-PD studies, n = 484) assessing dosing patterns during conversion to IPX066 from other levodopa formulations presented at the 68th Annual Meeting of the American Academy of Neurology.
    • 25 Nov 2015 According to Impax Laboratories' media release, the European Commission has granted marketing approval for levodopa/carbidopa modified release combination (NUMIENT) for the symptomatic treatment of adult patients with Parkinson's disease.
    • 25 Sep 2015 According to Impax Laboratories' media release, the Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted a positive opinion recommending levodopa/carbidopa modified release combination (NUMIENT) for the symptomatic treatment of adult patients with Parkinson's disease.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top